New hybrid Closed-Loop pump could ease diabetes management

NCT ID NCT05059860

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This study tested a hybrid closed-loop insulin delivery system (Control-IQ) in 30 adults with type 1 diabetes. The system combines an insulin pump with a continuous glucose monitor that automatically adjusts background insulin. Participants used the system for 52 weeks, and researchers measured blood sugar control, time in target range, and patient wellbeing. The goal was to see if this technology is effective and acceptable for people in Scotland.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Tandem Control-IQ hybrid closed-loop insulin delivery system (insulin pump + continuous glucose monitor)
What this could lead to
If successful, this system could help people with type 1 diabetes spend more time with their blood sugar in a healthy range and reduce dangerous highs and lows.
What could go wrong
This was a small, single-group study with only 30 participants, so results may not apply to everyone. The system still requires manual insulin doses at meals and is not yet routinely available in Scotland.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Professor John McKnight

    Edinburgh, Lothian, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.